In addition, the high affinity HER2 binding antibody radio-labeled with zirconium-89 was also applied for diagnosing HER2-positive metastases in patients with HER2-negative primary breast cancer and advanced HER2-positive breast cancer [72, 73]. Here, ERBB2 is linked to breast cancer.